Dr. Gulley Discusses Vaccine Responses

James L. Gulley, MD, PhD
Published: Tuesday, Sep 10, 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

The best definition of vaccine response, Gulley says, is the length of a patient's survival, as there are very few PSA responses and objective responses.

In the completed phase II trial analyzing PROSTVAC, robust responses were seen, as the placebo arm had a median overall survival of 16.1 months compared with about 25 months in the vaccine arm. In this trial, there was a PSA response of less than 5%.

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

The best definition of vaccine response, Gulley says, is the length of a patient's survival, as there are very few PSA responses and objective responses.

In the completed phase II trial analyzing PROSTVAC, robust responses were seen, as the placebo arm had a median overall survival of 16.1 months compared with about 25 months in the vaccine arm. In this trial, there was a PSA response of less than 5%.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x